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BK polyomavirus (BKPyV) is the most common viral pathogen among allograft patients. Increasing evidence links BKPyV to the
human oral compartment and to HIV-associated salivary gland disease (HIVSGD). To date, few studies have analyzed orally de-
rived BKPyV. This study aimed to characterize BKPyV isolated from throat wash (TW) samples from HIVSGD patients. The
replication potential of HIVSGD-derived clinical isolates HIVSGD-1 and HIVSGD-2, both containing the noncoding control
region (NCCR) architecture OPQPQQS, were assessed and compared to urine-derived virus. The BKPyV isolates displayed sig-
nificant variation in replication potential. Whole-genome alignment of the two isolates revealed three nucleotide differences that
were analyzed for a potential effect on the viral life cycle. Analysis revealed a negligible difference in NCCR promoter activity
despite sequence variation and emphasized the importance of functional T antigen (Tag) for efficient replication. HIVSGD-1
encoded full-length Tag, underwent productive infection in both human salivary gland cells and kidney cells, and expressed viral
DNA and Tag protein. Additionally, HIVSGD-1 generated DNase-resistant particles and by far surpassed the replication poten-
tial of the kidney-derived isolate in HSG cells. HIVSGD-2 encoded a truncated form of Tag and replicated much less efficiently.
Quantitation of infectious virus, via the fluorescent forming unit assay, suggested that HIVSGD BKPyV had preferential tropism
for salivary gland cells over kidney cells. Similarly, the results suggested that kidney-derived virus had preferential tropism for
kidney cells over salivary gland cells. Evidence of HIVSGD-derived BKPyV oral tropism and adept viral replication in human
salivary gland cells corroborated the potential link between HIVSGD pathogenesis and BKPyV.
BK polyomavirus (BKPyV) was first isolated from the urine of arenal allograft recipient in 1971 and was subsequently identi-
fied as a member of the small DNA tumor virus family (1). BKPyV
infection is ubiquitous, and seroconversion of up to 90% of the
world’s population by the age of 10 suggests that BKPyV transmis-
sion takes place during early childhood (2, 3). BKPyV primary
infection is asymptomatic and persists latently in the kidney of
immunocompetent individuals (4). Reactivation occurs under
immune-suppressed conditions, such as those experienced by pa-
tients receiving organ transplants and patients infected with HIV
(5). BKPyV reactivation among kidney transplant patients has
been associated with BKPyV nephropathy (BKN), which is by far
the most significant complication among renal transplant patients
(6–8).
The BKPyV genome (5 kb) is divided into three major compo-
nents: the early region, the late region, and the bidirectional viral
promoter, also known as the noncoding control region (NCCR).
The NCCR is the major determinant of in vitro replication (9) and
is arbitrarily divided into five block sequences: O (142 bp), P (68
bp), Q (39 bp), R (63 bp), and S (63 bp). The blocks contain the
origin of DNA replication and an array of transcription factor
binding sites (TFBS) (10–13). The late region encodes the agno-
protein and the structural proteins VP1, VP2 and VP3 (4, 14). The
early BKPyV genome region encodes the nonstructural viral pro-
teins: large, small, and mini-T antigen. Large T antigen (Tag) is
critical for the viral life cycle and drives the host cell into the S
phase (4, 15–17). Viral DNA synthesis is initiated by Tag’s helicase
activity, which unwinds the origin of replication within the viral
NCCR promoter (4) and subsequently recruits DNA synthetic
machinery (5). As the major BKPyV transforming viral oncopro-
tein, Tag interacts with both pRb and p53, instigating deregulated
cell growth. The Tag transformation potential is linked to the p53-
binding domain located near the carboxy terminus of the protein
(18). Upon initiation of DNA replication, Tag induces late viral
gene expression and represses early gene expression (19).
Given its historic link to renal pathogenesis, BKPyV has been
considered a kidney-tropic virus. Data however suggest a connec-
tion between BKPyV and the oral compartment. Both respiratory
(5) and fecal-oral (20) routes have been suggested as likely trans-
mission pathways. BKPyV DNA has been detected in tonsillar
biopsy specimens from immunocompetent children (21–23) and
nasopharyngeal aspirates of immunocompromised and immuno-
competent individuals (children and adults) (24). Finally, our
group has suggested a potential link between BKPyV and the oral
malady HIV-associated salivary gland disease (HIVSGD) (25, 26).
HIVSGD is among the most important HIV/AIDS-associated
lesions (27). HIVSGD pathogenesis is not well understood, and
present treatment strategies focus solely on symptom alleviation
(25). HIVSGD is characterized by salivary gland enlargement and
damage that incites xerostomia (28–31). HIVSGD diagnosis has
been tied to an increased risk of lymphoma development in HIV-
infected individuals (32). Finally, affected patients may suffer
stigma as HIVSGD’s outward appearance suggests HIV infection.
As for HIVSGD etiology, molecular evidence has previously estab-
lished an association between polyomaviruses (PyV) and salivary
gland pathology. Rodent models demonstrated that PyV injection
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resulted in salivary gland tumors in mice (33). In vivo, HIVSGD
patients shed 20-fold-higher levels of BKPyV in throat wash (TW)
and plasma (viremia) than HIV-positive patients without
HIVSGD and HIV-negative individuals (25). Moreover, our
group has demonstrated successful replication of a BKPyV labo-
ratory strain in human salivary gland cell lines (HSG and HSY) in
vitro (26). While contemporary advances have allowed efficient in
vitro cultivation of archetype BKPyV in kidney cells (providing
Tag in trans [34]), studies analyzing clinical BKPyV isolates have
been limited and kidney focused and have not assessed salivary
gland infection (9, 35–38). Molecular evidence demonstrates that
the in vivo replication compartments of urine- and plasma-de-
rived BKPyV are distinct (39, 40). Similarly, the salivary gland may
provide an additional BKPyV replication compartment in
HIVSGD (41).
In the present study, HIVSGD-derived BKPyV underwent suc-
cessful replication in human salivary gland (HSG) cells, providing
proof of concept that salivary glands of HIVSGD patients may
be replication competent. We further compared the replication
potential of TW-derived BKPyV clinical isolates to those of
urine- and laboratory-derived BKPyV in HSG cells and in kidney
cells (Vero). The replication potential of the clinical isolates
HIVSGD-1 and HIVSGD-2 differed greatly despite the two iso-
lates bearing the same NCCR architecture (OPQPQQS) and their
genomes differing by only three nucleotides. The replication inef-
ficiency of HIVSGD-2 was likely caused by the introduction of a
stop codon that produced a truncated Tag mutant. Interestingly,
HIVSGD-1 BKPyV encoded full-length Tag, replicated efficiently,
and displayed preferential tropism for salivary gland cells over
kidney cells, as suggested by quantitation of infectious virus.
MATERIALS AND METHODS
Patient information and sample collection. HIVSGD-positive individu-
als from The University of North Carolina at Chapel Hill (UNC) hospital
dental clinic were selected for throat wash (TW) collection under institu-
tional review board (IRB)-approved study guidelines. Urine samples from
HIV-negative patients were kindly donated and collected under the su-
pervision of V. Nickeleit at UNC Hospitals. Patient samples were centri-
fuged and DNase treated, and DNA was isolated via the Qiagen DNeasy
kit, as described by the manufacturer.
BKPyV NCCR sequencing. The BKPyV NCCR was PCR ampli-
fied (Vent polymerase; New England BioLabs, Inc.) with primers
BKPyVTU1F and BKPyVTU1R (37) from patient sample DNA, and the
products were subsequently sequenced by Genewiz, Research Triangle
Park, NC. NCCR amplification and sequencing was repeated a minimum
of three times per patient sample. The resulting NCCR nucleotide se-
quence was analyzed and aligned by the Vector NTI program. Vector NTI
identified the block motifs with a minimum similarity of 70% to original
block sequences (10).
wg BKPyV cloning. Whole-genome (wg) BKPyVs, including the nat-
urally occurring BamHI restriction fragment recognition sites, were PCR
amplified from clinical samples with primers BKPyVWGF (VP1 Forward,
5=-GCGGGATCCAGATGAAAACCTTAGG-3=) and BKPyVWGR (VP1
Reverse, 5=-GCGGGATCCCCCATTTCTGG-3=), using the Expand Long
Range dNTPack (Roche) as described by the manufacturer. Amplified wg
BKPyV products were purified by the QIAquick PCR purification kit
(Qiagen), as described by the manufacturer. Purified HIVSGD-2 and U1
wg BKPyV DNA was cloned via the TOPO TA cloning kit (Invitrogen) as
described by the manufacturer. Purified HIVSGD-1 DNA and pUC18
vector (2.6 kb) from Stratagene were digested separately with restriction
endonuclease BamHI, isolated, ligated via T4 DNA ligase (BioLabs).
DH5 bacterial cells (Invitrogen) were transformed with the HIVSGD-1,
HIVSGD-2, and MM ligation products. All bacterium-derived constructs
were isolated via QIAfilter plasmid Midi kit (Qiagen) after 24 h of incu-
bation at 37°C.
Virus, transfection, and infection conditions. The clinical BKPyV
strains cloned by us were HIVSGD-1, HIVSGD-2, and U1. The commer-
cially available infectious BKPyV was VR837 (ATCC). The laboratory-
derived Dunlop BKPyV clone was kindly donated by Michael J. Imperiale.
The laboratory-derived MM (ATCC 45026) BKPyV clone (42) is com-
mercially available. Interestingly, the MM BKPyV NCCR and Tag se-
quencing results obtained in this study were not homologous with previ-
ously published sequence (GenBank accession no. V01109).
BKPyV transfection. Cloned BKPyV was cut out of its respective
backbones by overnight (37°C) incubation with BamHI endonuclease;
HIVSGD-1 (pUC18), HIVGD-2 (pCR2.1), U1 (pCR2.1) and MM (ATCC
45026) (pBR322). wg BKPyV cloned into pCR2.1 was digested with en-
donuclease Taq1a for an additional 3 h at 65°C. wg BKPyV cloned into
pBR322 was digested with endonuclease BsAa1 for an additional 3 h at
37°C. All digested samples were run on a 2% ethidium bromide (EtBr)
agarose gel, and 5-kb bands were isolated in order to obtain wg BKPyV. wg
BKPyV DNA was purified via the QIAquick gel extraction kit (Qiagen), as
instructed by the manufacturer, and religated via T4 DNA ligase (Bio-
Labs) overnight at 16°C. Episomal viral DNA was subsequently purified
via phenol-chloroform. Single layers of HSG and Vero cells were passaged
by trypsinization (15 min), resuspended in 2% fetal bovine serum (FBS)
and 1% penicillin–streptomycin culture medium, and subsequently
seeded at 30% confluence. Episomal BKPyV was introduced into the
cells via lipid-mediated gene delivery, using TransIT-LU1 (Mirus) accord-
ing to the manufacturer’s protocol. Medium was changed 48 h posttrans-
fection (p.t.). Media and cells were collected at different time points for
further analysis.
Infection. Equal amounts of infectious clinical and laboratory strain
BKPyV (determined via fluorescent focus assay [FFA]) were used for in-
fection of HSG and Vero cells—illustrated in part 2 of the in vitro model
shown in Fig. 4. Supernatants of transfected HSG cells carrying infectious
BKPyV were passed through 0.45-m-pore filters and added to fresh HSG
and Vero cells.
Cell culture. Human submandibular salivary gland epithelial cells
(HSG cells) from adenocarcinoma (43) were obtained from B. Baum
(NIH) and maintained in McCoy’s 5A medium (Sigma) supplemented
with 10% fetal bovine serum (FBS) (Sigma) and 1% penicillin–strepto-
mycin (P/S) (Gibco). African green monkey kidney epithelial cells (Vero
cells), were obtained from the American Type Culture Collection
(ATCC), maintained in Dulbecco’s minimal essential medium (DMEM)
(Sigma) supplemented with 10% FBS and 1% P/S. Both cell lines were
incubated in humidified atmosphere at 37°C and 5% CO2.
Reporter construct formation. Primers BKPyVTU1F and BKPyVTU1R
(37) were used to amplify the BKPyV NCCR with flanking SacI restriction
fragment recognition sites via PCR (Vent polymerase; New England
BioLabs, Inc.). Amplified DNA products were purified by QIAquick PCR
purification kit (Qiagen), as described by manufacturer. Purified DNA
and pGL3-Basic vector (5 kb) from Promega were digested separately with
restriction endonuclease SacI, isolated, and ligated via T4 DNA ligase
(BioLabs). DH5 bacterial cells (Invitrogen) were transformed with
products, and constructs were isolated via the QIAfilter plasmid Midi kit
(Qiagen) after 24 h of incubation at 37°C.
BKPyV NCCR promoter activity. HIVSGD-1 and HIVSGD-2 BKPyV
NCCR promoter activities were measured with and without the presence
of wild-type large Tag in HSG cells via the luciferase (Luc) reporter assay
(pGL3 vectors; Promega). Cloned reporter constructs (1 g) were trans-
fected into HSG cells via lipid-mediated gene delivery, using TransIT-LU1
(Mirus) according to the manufacturer’s protocol. pCDNA RFP (red fluo-
rescent protein) was cotransfected along with or without Tag (0.5 g)
expression plasmid (in pCMV myc; kindly provided by L. Jeffers). The
Tag expression plasmid encoded VR837 BKPyV-derived full-length wild-
type large Tag. Cells were collected from each treatment at 48 h according
to the Promega luciferase assay protocol. Luc activities of the HIVSGD
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clones, pGL3 control vector (positive control [not shown]), and pGL3-
Basic vector (negative control) were measured in a microplate format by
the LMAX luminometer (Molecular Devices). HIVSGD Luc activity was
normalized to pGL3-Basic.
FFA. Vero cells (50% confluence) were infected with various volumes
of filtered (0.45-m pore) supernatant from transfected HSG cells and
incubated over 4 days. Where low levels of virus were present, higher
volumes were utilized in order to attain infection. These differences in
volumes used for Vero cell infection are accounted for in calculations of
fluorescence-forming units (FFU)/l (44). Vero cells were fixed in 50:50
methanol-acetone, air dried, and stored at 80°C overnight 4 days
postinfection (p.i.). Cells were rehydrated with phosphate-buffered saline
(PBS) the next day and incubated with anti-JC/BK polyomavirus primary
antibody NCL JCBK (Novocastra, Leica) at a 1:10 dilution in PBS for 30
min at 37°C and 30 min at room temperature (RT). The secondary anti-
body, goat anti-mouse-Alexa Fluor 488 (Life Technologies) conjugate at a
1:100 dilution in PBS, was added for 1 h at RT after the cells had been
washed twice with PBS. Cells were washed with PBS prior to addition of
DAPI (4=,6-diamidino-2-phenylindole)-DNA stain (1:10,000) and fluo-
rescence microscopy analysis (Olympus IX81). BKPyV-infected cells were
counted at a 20 magnification for a minimum of 10 fields per dish, and
FFU were calculated as described in reference 44. FFU values were
graphed for each treatment and are depicted as FFU/l or FFU/l  1 in
order to transform the zero values for the log10-based y axis.
BKPyV DNA detection via Southern blot hybridization. BKPyV epi-
somes were transfected (see above for BKPyV DNA and transfection de-
tails) into HSG cells at the following concentrations: 0.39 g Dunlop, 0.45
g U1, 0.72 g HIVSGD-1, 0.9 g MM, and 0.9 g pcDNA3 DNA. Dif-
ferential amounts of DNA were transfected for the DpnI resistance assay.
Hence, this assay was not intended to compare BKPyV replication levels.
All succeeding experiments were intended to evaluate relative viral repli-
cation levels, and transfections were done with equal amounts of BKPyV
DNA. Low-molecular-weight DNA was isolated from HSG cells 6 days p.t.
by a previously described modified Hirt method (45), digested by endo-
nucleases Sau3a and DpnI, electrophoresed on a 7% agarose gel, and
transferred onto a SuPerCharge (SPC) membrane by the Whatman Ny-
tran SPC Turbo blotter (General Electric), as described by the manufac-
turer. Membrane-associated BKPyV DNA was detected by hybridization
to randomly primed wg MM BKPyV (ATCC 45026) 32P-labeled DNA
probe and exposed to film (Kodak). The expected MM BKPyV DNA band
sizes according to mapped DpnI/Sau3a cut sites were 1,522, 681, 529, 451,
432, 346, 294, 230, 216, 129, and 116 bp.
Encapsidated viral DNA isolation and qPCR amplification. Trans-
fected and infected HSG and Vero cell supernatants were passed through
0.45-m-pore filters and DNase treated (Promega), removing debris/cells
and nonencapsulated viral DNA, respectively. DNA was isolated using the
QIAamp DNA blood minikit (Qiagen) as instructed by the manufacturer.
Viral load (VL) was quantified via quantitative real-time PCR (qPCR)
analysis with Roche LightCycler 480 SYBR green I master mix as a detector
in the Roche Light Cycler 480 by using previously published primers for
VP1 (46). BKPyV plasmid, kindly donated by V. Nickeleit, was used to
establish a standard curve and for subsequent quantification of encapsi-
dated viral genomes present in the cellular supernatant.
TEM. Three milliliters of transfected, infected, or control HSG and
Vero cell supernatant was spun at 13,000 rpm for 30 min at 4°C in order to
remove cellular debris and then at 290,000 rpm for 1 h at 4°C by ultracen-
trifugation in order to concentrate BKPyV and decrease the suspension
volume. Metal grids were subjected to purified supernatant and treated
with 2% uralic acetate for negative staining. Virus was subsequently visu-
alized via EM910 transmission electron microscopy (TEM) (Zeiss) utiliz-
ing a Gatan SC1000 camera.
Immunoblotting. Episomal BKPyV DNA (0.3 g) was transfected
into HSG cells, and whole-cell lysates were harvested with 1% SDS lysis
buffer 4 days posttransfection. Protein was quantified using the Bio-Rad
protein assay, and equal amounts were electrophoresed on a 10% Bis-Tris
polyacrylamide minigel (Invitrogen). Tag antibody PAb416 (Genetex)
(1:200) in 5% nonfat dry milk in 0.1% Tween 20 –PBS (PBS-T) was used
to detect Tag expression post-wg BKPyV transfection of HSG cells. c-
Myc-tagged Tag expression was detected via anti c-Myc antibody (Santa
Cruz) (1:1,000) post-reporter construct transfection of HSG cells. Actin
expression was detected via the (C-11)-R sc-1615-R antibody (Santa Cruz
Biotechnology) (1:1,000) in 5% nonfat dry milk (as described above).
Blots were washed in PBS-T three times for 10 min at RT and probed with
a horseradish peroxidase-conjugated secondary antibody (Promega) (1:
10,000), exposed to SuperSignal West Pico chemiluminescent substrate
(Thermo Scientific), and exposed to film (Kodak). Band intensity was
measured via densitometry. Relative band density was determined by nor-
malizing Tag to actin expression via Gene Tools from Syngene.
Nucleotide sequence accession numbers. The MM BKPyV NCCR
and Tag sequencing results obtained in this study have been submitted to
the GenBank database under accession no. KF445133 (BankIt1648707)
and KF445132 (BankIt1648650), respectively.
RESULTS
HIVSGD-1 and HIVSGD-2 BKPyV isolation and sequence anal-
ysis. Throat wash (TW) samples were collected from two HIV-
positive subjects with diagnosed HIVSGD. To obtain kidney-de-
rived BKPyV, urine was collected from an HIV-negative lung
transplant patient with diagnosed BKPyV nephropathy (BKN).
Patient demographic data (HIV status, other clinical status, age,
and sex) were collected, and BKPyV viral load (VL) was deter-
mined. Whole-genome (wg) BKPyVs were cloned from each sam-
ple, and the viral NCCR promoters were sequenced (Table 1). All
three clinical samples had high VLs ranging from 1.7  105 to
1.7  109 copies/ml. Similar to the laboratory strain MM, both of
TABLE 1 Demographics and viral characterization of clinical BKPyV isolatesa
Virus strain HIV status Clinical status or origin Source Age (yr)b BKPyV VL (copies/ml) NCCR
Patient derived
HIVSGD-1  HIVSGD TW 47 1.76  105 OPQPQQS
HIVSGD-2  HIVSGD TW 60 2.57  105 OPQPQQS
U1  BKN, lung transplant Urine 31 1.79  109 OPQ
Laboratory derived
Dunlop Laboratory-derived clone OPPPS
VR837 ATCC, infectious virus OPQPQS
MM ATCC, clone OPQPQQS
a Clinical whole-genome BKPyV was cloned from two HIV-associated salivary gland disease (HIVSGD) throat wash (TW) samples (HIVSGD-1 and HIVSGD-2) and one transplant
patient urine sample (U1) for in vitro analysis. All patients from whom the patient-derived strains were obtained were male. Laboratory strains Dunlop, VR837, and MM served as
laboratory control strains. NCCR, noncoding control region; BKN, BKPyV nephropathy.
b Patient age at time point of sample collection.
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the HIVSGD-derived BKPyV isolates had OPQPQQS NCCR
block alignments. The transplant urine sample carried BKPyV
with a OPQ NCCR block alignment. The NCCR architectures of
previously studied laboratory strains MM, Dunlop, and VR837
BKPyV were sequenced as a control measure and recovered cor-
rectly (Table 1). Alignment of the whole-genome nucleotide se-
quences of HIVSGD-1 and HIVSGD-2 BKPyV detected 99.9%
whole-genome similarity. The three single-nucleotide differences
were as follows: (i) a single-base-pair thymidine (T) deletion be-
tween sequences that encoded agnoprotein and VP2 (Fig. 1A, 1),
(ii) a thymidine/cytidine transition (T/C) within the NCCR (Fig.
1A, 2), and (iii) a single-base-pair adenosine (A) deletion within
the Tag coding sequence (Fig. 1A, 3). All three mutations were
analyzed for potential biological significance. The T deletion lo-
cated between the genes coding for agnoprotein and VP2 was as-
sumed to be least important, since this mutation did not affect
either of the adjacent VP2 and agnoprotein open reading frames
(Fig. 1B).
The HIVSGD-1 and HIVSGD-2 NCCRs differed by a T/C
transition located within the S block of the viral promoter. To
assess the potential biological significance of this nucleotide tran-
sition, putative human transcription factor binding sites (TFBS)
were predicted within this region of the NCCR. Identical TFBS
(Smad3, Smad4, C/EBP, AP-2A, and E47) were predicted for
both HIVSGD-1 and HIVSGD-2 (Fig. 2A). Next, in vitro pro-
moter activity was assessed to determine whether the transition
led to differential promoter activity despite homologous TFBS.
HIVSGD-1 and HIVSGD-2 NCCR-pGL3 reporter constructs
were generated in the early and in the late directions. NCCR re-
porter and pGL3 basic control constructs were cotransfected with
(black bars) and without (white bars) full-length VR837-derived
Tag in HSG cells (Fig. 2B and C). Promoter activity was deter-
mined as fold luciferase (Luc) induction over pGL3-Basic. Tag
protein expression was confirmed by immunoblot analysis. Sim-
ilar promoter activity levels were achieved for both HIVSGD-1
and HIVSGD-2 in the early direction, independent of Tag’s pres-
ence or absence: 2.7- versus 2.4-fold and 12- versus 11.4-fold in-
duction, respectively (Fig. 2B). HIVSGD-2 promoter activity was
higher than that of HIVSGD-1in the late direction independent of
Tag’s presence or absence: 54- versus 31-fold and 7- versus 2-fold
induction, respectively (Fig. 2C). Overall, NCCR activity differ-
ences between HIVSGD-1 and HIVSGD-2 were nominal. Func-
tional Tag is known to suppress the BKPyV NCCR in the early
direction and induce it in the late direction (4). Hence, the obser-
vations made here suggested that the cloned HIVSGD NCCRs
were functional within the reporter constructs.
The adenosine (A) deletion detected within the Tag nucleotide
sequence of HIVSGD-2 but not within HIVSGD-1 was analyzed
for potential biological significance (Fig. 3A). ClustalW (47)-
based Tag amino acid sequence alignment of HIVSGD-1,
HIVSGD-2, and the simian virus 40 (SV40) pRb binding domain
(1GH6:ChainA) located the deletion distal to the pRb binding site
of the Tag viral protein and detected 82.5% sequence identity
between SV40 and HIVSGD-1 full-length Tag. The deletion was
predicted to introduce an early stop codon that truncated the orig-
inal Tag nuclear translocation signal from PKKKRKV to PKKKER
(Fig. 3B). HIVSGD-2 Tag, which carried the early stop codon, was
calculated to express a Tag mutant of 15.6 kDa instead of the
80.5-kDa full-length Tag expressed by BKPyV HIVSGD-1 (Fig.
3C). A schematic model of full-length HIVSGD-1 and truncated
HIVSGD-2 Tag was created using the HHPred and MODELLER
structural prediction tools (48). This truncating deletion was
likely the most significant of the three nucleotide mutations due to
the truncation and the importance of Tag for the viral life cycle.
Assessment of HIVSGD BKPyV replication in vitro: posttrans-
fection. The posttransfection replication potential of HIVSGD-1 and
HIVSGD-2 BKPyV was assessed within human salivary gland and
kidney cells (Fig. 4). BKPyV clones of throat wash-derived
HIVSGD-1 and HIVSGD-2, kidney-derived U1, and laboratory
strains MM and Dunlop were used for in vitro analysis (Table 1).
Laboratory strain VR837 was used as an infectious BKPyV-posi-
tive control.
The capacity for de novo BKPyV DNA synthesis post-salivary
gland cell (HSG)-transfection was determined. HSG cells were
transfected with HIVSGD-1 (encoding full-length Tag), U1, MM,
and Dunlop BKPyV episomes and evaluated using a restriction
enzyme resistance assay. The DpnI/Sau3a enzyme resistance as-
say allowed discernment between transfected BKPyV genomes
(methylated bacterial plasmid DNA) and BKPyV genomes made
de novo (nonmethylated eukaryotic DNA). DNA was isolated 6
days posttransfection (p.t.), digested with DpnI and Sau3a, and
visualized by Southern blotting (Fig. 5). DpnI and Sau3a cleaved
the same restriction sites, but DpnI digested exclusively bacterial
and not eukaryotic methylation patterns, while Sau3a digestion
was methylation pattern independent (9, 49). While multiple
bands were detected post-Sau3a digestion, clear differences in the
VP2 protein  AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA    MAAGAAAAAAAAL AAAAL  
HIVSGD-1  GACTCTGTAAAAGACTCCTAGGTAAGTAATCCCTTTTTTTTTGTATTTCCAGGTTCATGGGTGCTGCTCTAGCACTT 
HIVSGD-2  GACTCTGTAAAAGACTCCTAGGTAAGTAATCCCTTTTTTTT-GTATTTCCAGGTTCATGGGTGCTGCTCTAGCACTT 
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FIG 1 Whole-genome sequence comparison between HIVSGD BKPyV isolates revealed three polymorphisms. (A) The schematic shows the linearized BKPyV
genome and encoded viral proteins. Black bars and numbers denote the three single-base-pair polymorphisms (black bars 1 to 3) differentiating whole genomes
HIVSGD-1 and HIVSGD-2: 1, thymidine deletion between the open reading frames (ORFs) coding for agnoprotein and VP2; 2, thymidine-to-cytidine transition
within the noncoding control region (NCCR); 3, adenosine deletion within the ORF coding for Tag. (B) The depicted DNA stretches show the thymidine deletion
between the ORFs coding for agnoprotein and VP2 found within HIVSGD-2 but not HIVSGD-1.
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FIG 2 Similar trends in promoter activity were detected for HIVSGD-1 and HIVSGD-2 BKPyV. (A) The schematic represents the HIVSGD BKPyV NCCR block
architecture and the thymidine/cytidine transition within the S block. Identical human putative transcription factor binding sites (TFBS) were predicted for HIVSGD-1
and HIVSGD-2 despite the transition: E47, Smad3, Smad4, C/EBP (C/EBP), and AP-2A (AP). (B and C) Graphs show NCCR luciferase (Luc) activity in the presence
and absence of wild-type Tag for the early (B) and late (C) promoter directions. Luc activity was depicted as fold induction relative to pGL3-Basic (pGL3 B), and error
bars represent standard deviations. Tag (Myc-tagged Tag, 82-kDa) and actin (45-kDa) protein expression were visualized by immunoblotting.
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banding patterns are detected upon comparison to DpnI digestion
for both HIVSGD-1 and MM BKPyV DNA. The detection of
HIVSGD-1 (Fig. 5B, lane 5 versus lane 6) and MM (Fig. 5A, lane 7
versus lane 8) DNA bands post-Sau3a digestion but not post-
DpnI digestion, in the range of 100 to 1,600 bp suggested that the
detected BKPyV DNA was of eukaryotic origin, and therefore
HIVSGD-1 and MM BKPyV underwent whole-genome replica-
tion in HSG cells. While not all bands are distinct, they corre-
sponded to mapped MM BKPyV (GenBank accession no.
V01109.1) DpnI/Sau3a cut sites resulting in fragments ranging
from 1 to 1.6 kb. BKPyV DNA bands between 1.6 and 5 kb are
likely due to incomplete digestion, and prominent bands at 5 kb
(Fig. 5A, lane 7) correspond to whole-genome BKPyV, as previ-
ously reported (9). In summary, the enzyme resistance assay sug-
gested that both HIVSGD-1 and MM BKPyV DNA were made de
novo in transfected HSG cells. The intention of this assay was not
to compare BKPyV replication levels but to firmly establish that
HIVSGD-1 BKPyV could replicate its DNA in human salivary
gland cells. Faint kidney-derived U1 BKPyV DNA bands were
visualized upon long exposure, suggesting potential replication
(Fig. 5A, lanes 3 and 4).
Tag protein expression reflects successful transition through
the early BKPyV life cycle. The consequence of the HIVSGD-2 Tag
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FIG 3 HIVSGD BKPyV Tag sequence analysis revealed a premature stop codon in HIVSGD-2. (A) The depicted BKPyV DNA sequences show the Tag adenosine
(A) deletion found within HIVSGD-2 but not HIVSGD-1. (B) Alignment of the Tag amino acid sequences of HIVSGD-1, HIVSGD-2, and the SV40 pRb binding
domain (1GH6 chain A) via ClustalW localized the deletion distal to the pRb binding domain. The deletion was predicted to alter the original PKKKRKV nuclear
translocation signal found within HIVSGD-1 into PKKKER (see the box) in HIVSGD-2. (C) The deletion was further predicted to introduce an early stop codon
(see the box) and subsequently truncate HIVSGD-2 Tag. Schematic models of full-length HIVSGD-1 Tag (wild type [wt], 80.5-kDa protein) and truncated
HIVSGD-2 Tag (15.6-kDa protein) were created using the HHPred and MODELLER structural prediction servers (sequence and model coloring coincide). On
the left is depicted the full-length sequence, and on the right are depicted the truncated sequence and schematic models, respectively.
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protein expression were determined 5 days post-HSG transfection
and compared among clinical isolates HIVSGD-1, HIVSGD-2,
and U1 and laboratory strain MM BKPyV by Western blotting
(Fig. 6A). The laboratory strain Dunlop BKPyV was not further
assessed as HSG cells were unable to support DNA replication
(Fig. 5). The harvest time point was selected based on previous
studies that detected Tag protein expression 4 days p.t. (26, 34).
Tag was normalized to expression of -actin, a loading control
(Fig. 6B). The highest Tag expression was detected for HIVSGD-1
(full-length, 80 kDa), followed by MM and U1 BKPyV (Fig. 6B).
Both full-length and truncated (15 kDa [not shown]) forms of
Tag protein were below the level of immunoblot detection for
HIVSGD-2. No Tag protein was detected in mock-infected nega-
tive controls.
To further evaluate the replication potential of each isolate,
encapsulated BKPyV virions released from transfected HSG cells
were quantified. At 6 days p.t., BKPyV viral loads (VLs) of filtered
and DNase-treated media from transfected HSG cells were deter-
mined by quantitative real-time PCR (qPCR). The supernatant of
all BKPyV-transfected HSG cells carried encapsulated BKPyV
DNA. MM- and HIVSGD-1-transfected HSG cells supported
similarly high VLs, with 3.5  107 and 2.4  107 copies/l, respec-
tively. U1 and HIVSGD-2 VLs were significantly lower than that of
HIVSGD-1, at 1.4  103 and 2.6  102 copies/l, respectively (Fig.
7A). Differences between HIVSGD-2 and U1 VLs each compared
to HIVSGD-1 were highly statistically significant (P 	 0.0001).
HIVSGD-1 was the most efficient replicator, followed by MM, U1,
and HIVSGD-2. Interestingly, low levels of HIVSGD-2 virions
were detected, despite the Tag mutation and lack of Tag expres-
sion, as described above. To confirm the presence of BKPyV viri-
ons, HSG supernatant (6 days p.t.) was analyzed by transmission
electron microscopy (TEM). BKPyV particles were detected by
TEM for HIVSGD-1 and MM but were not detected for lower
replicators U1 or HIVSGD-2 BKPyV (Fig. 7B). Morphological
features of HIVSGD-1 and MM BKPyV were reminiscent of
icosahedral (T 	 7) symmetrical BKPyV particles with a diameter
of 45 nm (4) that have been visualized in in vitro-derived super-
natants (34) and patient-derived fluids (50).
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FIG 4 Multistep salivary gland cell in vitro system for viral fitness assessment.
The diagram shows the two parts of the in vitro model. Part 1 represents
human salivary gland cell (HSG) transfection with episomal BKPyV, and part
2 represents HSG and Vero cell infection with transfection-derived BKPyV.
The following analyses were performed: Western blotting (WB) for Tag pro-
tein expression, Southern blotting (SB) for de novo BKPyV DNA expression,
quantitative real-time PCR (qPCR) for viral load (VL) determination, fluores-
cent focus assay (FFA) for infectious virus quantification, and transmission
electron microscopy (TEM) for virion morphology characterization.
































































































































   
 
  












FIG 5 HIVSGD-1 and MM BKPyV DNA were made de novo in human
salivary gland cells. Panels A and B show the same blot at different exposures
(A, 15 min and B, 1 min). Low-molecular-weight DNA was isolated 6 days
post-HSG cell transfection with Dunlop, MM, U1, and HIVSGD-1 BKPyV
DNA. pcDNA3 DNA transfection served as the negative control. Isolated DNA
was digested with endonucleases DpnI (D1) and Sau3a (S3) and visualized via
Southern blotting. DpnI and Sau3a cut the same sites, but DpnI recognizes
exclusively bacterial and not eukaryotic methylation patterns. DpnI resistance
assay allows differentiation of BKPyV DNA that was transfected (of bacterial
origin) and BKPyV DNA that was made de novo by HSG cells (of eukaryotic
origin). Detection of stronger DNA bands (at expected size) post-Sau3a diges-
tion versus post-DpnI digestion, as seen for BKPyV HIVSGD-1 and MM DNA
(lane 5 versus lane 6 and lane 7 versus lane 8), suggested that BKPyV DNA was
made de novo by transfected HSG cells. No Dunlop BKPyV DNA (lanes 1 and
2) and faint U1 (lanes 3 and 4) bands were found.
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The titer of infectious HSG transfection-derived BKPyV vi-
rions was determined via the fluorescent focus assay (FFA).
FFA provided antibody-based detection of intracellular PyV
proteins postinfection (44). Vero cells were exposed to HSG
cell supernatant containing BKPyV and incubated for 4 days,
and infected cells were quantified. Intracellular PyV structural
proteins (VP1, VP2, and VP3 [green]) were detected for
HIVSGD-1, HIVSGD-2, and laboratory strain MM but not for
U1 BKPyV or mock infection (Fig. 8). As in previous studies
(44), PyV proteins were detected exclusively in the nucleus
(DAPI [blue]) of infected Vero cells (Fig. 8C). Infectious
BKPyV VR837, which has been shown to replicate permissively
in HSG and Vero cells (26) served as a positive control.
HIVSGD-1, MM, and HIVSGD-2 scored 80, 50, and 1 FFU/l,
respectively. HIVSGD-1 infected significantly more cells than
laboratory strain MM (P 	 0.01) and HIVSGD-2 (P 	 0.0001)
(Fig. 8B). Despite detectable U1 VLs by qPCR, U1 BKPyV in-
tracellular proteins were not detected by FFA.
Clinical and laboratory strain BKPyV postinfection. Infec-
tions were performed to assess cell-type-dependent reproduction
of HSG-derived BKPyV (Fig. 4, part 2). HSG and Vero cells were
simultaneously infected with equal amounts of BKPyV that orig-
inated from HSG cell transfections—an equivalent of 200 FFU for
each viral substrain (Fig. 4, part 1). Encapsulated BKPyV virions
released from infected HSG and Vero cells were quantified by
qPCR at 2, 4, 6, and 8 days postinfection (p.i.). HIVSGD-1 and
MM BKPyV VLs increased by 4 and 3 orders of magnitude, re-
spectively, in HSG cells over 8 days p.i. In Vero cells, HIVSGD-1
and MM BKPyV VLs increased by 5 and 4 orders of magnitude,
respectively, over 8 days p.i. (Fig. 9A). These results indicated that
HSG cell transfection-derived HIVSGD-1 and MM BKPyV were
infectious and underwent replication in both HSG and Vero cells.
Encapsulated HIVSGD-2 and U1 BKPyV DNAs were not detected
from either cell type. Interestingly, the VL kinetics of BKPyV in
Vero and HSG cells were similar upon infection, suggesting that
virion production was equally efficient in both HSG and Vero cells
FIG 6 HIVSGD-1 but not HIVSGD-2 expressed BKPyV Tag protein post-HSG cell transfection. (A) Protein bands visualized via Western Blotting (WB). Total
cell lysates were harvested 5 days p.t., and proteins were analyzed by WB, probing for viral Tag (82 kDa) and cellular -actin (45 kDa; loading control). The
Tag expression levels ranked from high to low as HIVSGD-1, MM, and U1 BKPyV. No HIVSGD-2 Tag protein was detected. (B) The chart shows the relative
protein band density, measured by densitometry and normalized to actin.
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postinfection. TEM confirmed BKPyV virion presence and mor-
phology (8 days p.i.). Visualized particles were classified as BKPyV
based on capsid morphology and diameter. BKPyV particles were
detected in the media of HSG cells infected with HIVSGD-1 and in
Vero cells infected with HIVSGD-1 and MM BKPyV (Fig. 9B). U1
and HIVSGD-2 virions were not identified upon inspection. MM
BKPyV-infected HSG cell medium was not analyzed by TEM.
The infectivity of HSG- and Vero cell-derived BKPyV progeny
was assessed by FFA (Fig. 10). Vero cells were infected with HSG
and Vero cell media 8 days p.i. and incubated over 4 days. PyV
structural proteins (VP1, VP2, and VP3 [green]) were detected at
289 FFU/l for VR837 (positive control), and no viral proteins
were detected in mock infections (Fig. 10A). HSG cell infection-
derived MM and HIVSGD-1 BKPyV both scored 48 FFU/l,
whereas U1 scored 5 FFU/l (9.6-fold less). No infectious
HIVSGD-2 BKPyV was detected (Fig. 10B). Interestingly, much
lower FFUs were detected in Vero cell infection-derived MM and
HIVSGD-1 BKPyV (10 FFU/l and 19 FFU/l, respectively) than
in these viruses of HSG cell origin (48 FFU/l). These results
indicated that HIVSGD-1 and MM BKPyV were more infectious
if originating from HSG (salivary gland) cells than Vero (kidney)
cells (Fig. 10C and D), despite the detection of similar VLs in both
cell types (Fig. 9). Most strikingly, among Vero cell-derived
BKPyV, the kidney-derived virus U1 (58 FFU/l) was most infec-
tious and displayed 5.8-fold-higher FFU/l than MM and 3-fold-
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FIG 7 Significantly higher viral loads were detected for HIVSGD-1 than for HIVSGD-2 BKPyV post-HSG cell transfection. (A) The chart shows viral loads (VLs)
measured from the supernatant of HSG cells transfected with BKPyV genomes. HSG cell supernatant was harvested 6 days p.t., filtered, and DNase treated, and
BKPyV was quantified via qPCR and is depicted as BKPyV copies/l. VL levels are ranked from high to low as MM, HIVSGD-1, U1, and HIVSGD-2 BKPyV. The
P values were determined via one-way analysis of variance (ANOVA), and error bars represent standard deviations. (B) Representative images visualizing
HIVSGD-1 and MM BKPyV virions from HSG cell supernatant via transmission electron microscopy (TEM) 6 days p.t. (black arrows).
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tectable VLs (Fig. 9), U1 (kidney-derived) BKPyV scored higher
FFU originating from kidney (Vero) cells than salivary gland
(HSG) cells (Fig. 10C and D). As expected, the lack of measurable
HIVSGD-2 BKPyV VL was associated with an inability to detect
infected cells, whether Vero or HSG cell derived.
DISCUSSION
HIV-associated salivary gland disease (HIVSGD) is among the
most significant HIV/AIDS-associated oral lesions (25). Previ-
ously published data by our group suggested a correlation be-
tween HIVSGD and BKPyV (25, 26). To our knowledge, we are
the first to analyze HIVSGD BKPyV and to establish a fully per-
missive salivary gland cell culture model supporting productive
replication of clinical BKPyV isolates. The present study assessed
replication differences in genomically similar HIVSGD isolates
and compared a kidney-derived clinical isolate to HIVSGD clini-
cal isolates. We assessed the noncoding control region (NCCR) of
these isolates and determined in vitro replication capabilities in
both salivary gland and kidney cells. Importantly, this study pro-
vides evidence for differences in cell tropism based on the cell
origin of BKPyV.
Three clinical BKPyV isolates were characterized and com-
pared: HIVSGD-1 and HIVSGD-2 were isolated from the throat
wash (TW) samples of HIVSGD-positive patients, and U1 was
isolated from the urine sample of an HIVSGD-negative transplant
patient (kidney-associated isolate). BKPyV viral loads (VLs) from
all three clinical samples were high and ranged from 1.7  105 to
1.7  109 copies/ml, likely reflecting immunosuppression in each
instance. We previously established that VLs in healthy individu-
als and in HIV-positive patients without HIVSGD were 3 to 4 logs
lower than the VLs detected in HIVSGD-positive individuals (25).
Comparable VLs in the HIVSGD-associated oral fluid samples
and in the urine sample from a transplant patient diagnosed with
BKN suggested a significant increase in shed virus, perhaps at
pathogenic levels.
Whole-genome sequence alignment of the two HIVSGD
clones (HIVSGD-1 and HIVSGD-2) determined 99.9% similarity,
despite three point mutations (Fig. 1A). A thymidine deletion was
detected between the open reading frames (ORFs) that encoded
agnoprotein and VP2 (Fig. 1A, bar 1). The deletion was outside the
respective ORFs and was therefore unlikely to affect replication.
Nevertheless, it was possible that the mutation could have inter-
fered with VP2 gene expression via disruption of a potential inter-
nal ribosome entry site (IRES) that was present in this region of
the BKV genome. However, the affected nucleotide stretch did not
contain a known IRES (Fig. 1B).
The BKPyV NCCR is the main determinant of in vitro replica-
tion (9), and rearrangements confer significant differences in rep-
FIG 8 Infectious HIVSGD-1, HIVSGD-2, and MM BKPyV progeny were
detected post-HSG cell transfection. (A) Representative images showing
HIVSGD-1-, HIVSGD-2-, MM-, and VR837 BKPyV-infected Vero cells.
Transfected HSG cell supernatant was transferred onto Vero cells, and BKPyV-
infected cells were visualized via FFA. BKPyV protein (green) was detected in
the nucleus (DAPI [blue]). VR837 infection served as the positive control (Pos.
Ctrl.). The number of infected cells was counted for each treatment in a min-
imum of 10 fields at 20 magnification, and FFU/l values were calculated.
(B) FFU values were graphed for each treatment and are depicted as FFU/l 
1. The error bars represent standard deviations, and the P values were assessed































568 jvi.asm.org Journal of Virology
FIG 9 HIVSGD-1 and MM BKPyV exhibited similar replication kinetics in HSG and Vero cells with increasing viral loads postinfection. (A) The chart at the top
shows viral loads (VLs) in BKPyV copies/l, measured from the supernatant of infected HSG and Vero cells, 2, 4, 6, and 8 days p.i. Filtered supernatant from
transfected HSG cells was used to infect HSG (black) and Vero (white) cells at equal viral loads. Supernatant from infected cells was harvested, filtered, and DNase
treated, and BKPyV VL was quantified via qPCR. BKPyV HIVSGD-1 VLs increased over 6 orders of magnitude and MM VLs over 5 orders of magnitude during
the 8 days p.i. Encapsulated HIVSGD-2 DNA and U1 BKPyV DNA were not detected. Error bars represent standard deviations. Graphed VLs from infected HSG
cells and Vero cells show similar growth kinetics for BKPyV HIVSGD-1 and MM. (B) HIVSGD-1 (Vero- and HSG cell-derived) and MM (Vero cell-derived) BK
virions were detected under TEM 8 days p.i. MM BKPyV-infected HSG supernatant was not analyzed. No virions were detected for HIVSGD-2, U1, and mock
infection in HSG or Vero cells (data not shown). Mock infections were accomplished by using supernatant from mock-transfected cells.
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lication capacity, transforming potential, host cell permissivity,
and tropism (12, 37, 39, 40, 51–53). NCCR rearrangements are
defined as changes in the NCCR block sequences compared to the
archetype. The archetypic BKPyV substrain, defined by carrying
the OPQRS NCCR architecture, is commonly shed in urine (5).
We sequenced the BKPyV NCCRs of the three clinical isolates and
detected a common signature block alignment, OPQPQQS,
among the HIVSGD TW samples. NCCR block divergence from
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FIG 10 Cell-type-dependent differential infection was detected based on viral origin. (A) Representative images of FFA-positive (VR837 BKPyV infection; 289 FFU/l)
and FFA-negative (mock infection; no virus detected) controls. Infected cells (green) and nuclei (blue) were quantified, and FFU/l values were calculated. A magnifi-
cation (Mag.) of 60 is shown for the middle row. (B) Representative images of HIVSGD-1-, U1-, and MM BKPyV-infected cells are shown. Supernatant of infected
HSG cells (8 days p.i.) was filtered and transferred onto Vero cells. HIVSGD-1 and MM yielded 48 FFU/l. U1 yielded 5 FFU/l. No infected cells were detected for the
HIVSGD-2 treatment. (C) Representative images of HIVSGD-1-, U1-, and MM BKPyV-infected cells are shown. Supernatant of infected Vero cells (8 days p.i.) was
filtered and transferred onto Vero cells. Infected cells were visualized via FFA (green) and quantified, and FFU values were calculated. HIVSGD-1 yielded 19 FFU/l, MM
yielded 10 FFU/l, and U1 yielded 58 FFU/l. No infected cells were detected for the HIVSGD-2 treatment. (D) The chart shows FFU values for each treatment, depicted
as FFU/l. Black bars, HSG cell infection-derived BKPyV; white bars, Vero cell infection-derived BKPyV. Error bars represent standard deviations.
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archetype into rearranged (rr) variants, as detected in this study,
have been previously recorded both in vivo (16, 51, 54, 55) and in
vitro (16, 35, 37, 38, 56). Prior studies among transplant recipients
with prolonged viremia illustrated that rearranged architectures
eventually became dominant over the archetype (39). The rr
NCCR OPQPQQS may reflect the dominant architecture within
these HIVSGD patients and may represent a stable and biologi-
cally significant variant. Despite VP1-based classification of
BKPyV genotypes (57), BKPyV variants are categorized by NCCR
block sequence (58). The OPQPQQS NCCR block alignment was
previously described in laboratory strain MM; however, to our
knowledge, other clinical isolates carrying this architecture have
not been reported. Importantly, underlying nucleotide differences
distinguished the HIVSGD clinical isolates from MM. Inclusion of
well-described BKPyV laboratory strains during NCCR genotyp-
ing corroborated the authenticity of our results.
HIVSGD-1 and MM BKPyV shared the NCCR OPQPQQS
block architecture and exhibited similar levels of Tag expression,
virion production, and infectivity. Similar replication efficiency
between HIVSGD-1 and MM may be explained by the analogous
NCCR architecture. HIVSGD-2, however, consistently lacked
signs of efficient in vitro replication. While HIVSGD-2 shared
the overall NCCR architecture with HIVSGD-1 and MM, the
HIVSGD-2 NCCR S block contained a thymidine (T)/cytidine
(C) transition (Fig. 1A, no. 2). This NCCR transition did not lead
to differential prediction of putative human TFBS (Fig. 2A) or to
differences in the early promoter activity in the presence or ab-
sence of full-length Tag (Fig. 2B) and thus was an unlikely con-
tributor to differences in replication efficiency. Interestingly, the
HIVSGD-2 promoter in the late direction was induced more
readily, in the presence or absence of full-length Tag, than the high
replicator HIVSGD-1 (Fig. 2C). Based on in vitro results that
characterized HIVSGD-2 as an inefficient replicator, higher
HIVSGD-2 promoter activity in the late direction was unlikely to
affect its viral fitness. Despite the well-documented importance of
the NCCR for BKPyV replication, the S block point mutation
appeared unlikely to affect viral fitness.
Inefficient HIVSGD-2 replication was likely associated with
the adenosine deletion distal to the Tag pRb binding domain. This
point mutation was predicted to introduce an early stop codon
and modify the nuclear translocation signal (Fig. 3A and B). This
resulted in the expression of a truncated form of Tag that de-
creased the predicted Tag protein size from 80.5 kDa to 15.6 kDa.
The mutant form of Tag lost the origin-binding domain (OBD),
p53 site, and ATP/helicase domain (Fig. 3C) and carried a modi-
fied version of the nuclear translocation signal (Fig. 3A and B).
Tag is central to genome replication and PyV life cycle completion
(59–61). Insufficient Tag expression has been shown to impede
archetypic BKPyV replication in vitro (34). It is therefore likely
that insufficient Tag expression dramatically inhibited HIVSGD-2
replication. Remarkably, the isolation of HIVSGD-2 BKPyV from
the TW sample and generation of progeny virus served as evidence
of minimal HIVSGD-2 replication both in vivo and in vitro.
HIVSGD-2 virus was detected at low levels posttransfection, as
determined by qPCR (VL measurement in Fig. 7), and was infec-
tious, as measured by FFA (Fig. 8). Two potential mechanisms
may have allowed for low levels of HIVSGD-2 replication. (i) In
vivo, the first mechanism is provision of Tag in trans by other
BKPyV substrains. Broekema et al. demonstrated that provision
of overexpressed Tag allowed the cultivation of archetype BKPyV,
a typically low in vitro replicator (34). (ii) In vitro and in vivo, by
the second mechanism, low levels of full-length Tag could be pro-
duced by ribosomal frameshifting. Ribosomal frameshifting com-
monly takes place in retroviruses facilitated by a slippery A/T-rich
heptanucleotide sequence that allows for low protein expression
despite the presence of a stop codon (62). The A/T-rich stretch
within HIVSGD-2 BKPyV Tag located 5= to the stop codon may
allow for frameshifting in the context of BKPyV. Moreover, pre-
mature truncations of Tag have been detected in other PyVs.
Merkel cell polyomavirus (MCV) mutations that prematurely
truncated Tag were found in strains derived from human tumors
but not in benign sources and have been postulated to render
MCV more malignant (60). Likewise, there is the potential that
truncation of HIVSGD BKPyV Tag not only may decrease repli-
cation efficiency but also may be associated with increased in vivo
transformation potential.
HIVSGD BKPyV in vitro viability was assessed by transfection
(Fig. 4, part 1) and infection (Fig. 4, part 2) of salivary gland cells
and kidney cells. Kidney cells represented the historically de-
scribed replication niche. HIVSGD BKPyV fitness was compared
to those of both kidney-derived substrain U1 and laboratory
strain MM (Table 1). We hypothesized that shed HIVSGD isolates
were likely to replicate in salivary gland cells in vivo, and by exten-
sion, these isolates would replicate efficiently within HSG cells in
vitro. Indeed, HIVSGD-1 consistently exhibited high replication
competence in salivary gland cells. HIVSGD-1 and MM demon-
strated the highest posttransfection replication efficiency com-
pared to HIVSGD-2 and kidney-derived U1, as determined by
viral protein concentrations (Fig. 6), VLs (Fig. 7), and significant
levels of infectious BKPyV progeny (Fig. 8). Furthermore, the high
replication capability of HIVSGD-1 was consistent during infec-
tion of HSG and Vero cells (Fig. 4, part 2) with high levels of HSG
cell-released progeny virus (Fig. 9). HIVSGD-1, MM, and U1 but
not HIVSGD-2 completed a full life cycle upon secondary viral
passage.
HIVSGD-1 and MM VL measurements suggested equally effi-
cient levels of virion production upon infection of HSG and Vero
cells, as the replication kinetics were very similar (Fig. 9). Differ-
ences in scored infectious units, however, suggested that while
replication kinetics and progeny output were consistent for
HIVSGD-1 and MM, subsequent infectivity was distinct, depend-
ing on cell type and virus origin comparing HIVSGD-1 or MM
versus kidney-derived U1 (Fig. 10D). When HIVSGD-1 and MM
BKPyV originated from HSG cells rather than Vero cells higher
FFU were scored. Likewise, when kidney-derived U1 BKPyV orig-
inated from Vero cells rather than HSG cells, higher FFU were
scored. Differential infectivity suggested HIVSGD BKPyV dis-
played preferential tropism for salivary gland cells over kidney
cells. Similarly, U1 displayed preferential tropism for kidney cells
over salivary gland cells. Additionally, we recorded a dramatic
increase in viral progeny production for Vero cell-derived U1 dur-
ing the 4-day Vero cell incubation for the FFA (Fig. 10). This was
interesting since U1 VLs were below the level of detection for
qPCR quantification at 8 days p.i. (Fig. 9) and suggested that kid-
ney-derived U1 BKPyV was able to produce infectious progeny
more efficiently in kidney cells (58 FFU/l) than HSG cells (5
FFU/l) (Fig. 10). Overall, differential infectivity depending on
cell origin suggested that U1 displayed kidney tropism and
HIVSGD BKPyV displayed salivary gland tropism, consistent with
their respective in vivo kidney and salivary gland origins. Interest-
Oral BK Virus in Culture
January 2014 Volume 88 Number 1 jvi.asm.org 571
ingly, previous studies comparing levels of laboratory strain
BKPyV replication among a wide range of different cell lines de-
tected few differences in replication potential and did not indicate
specific cellular tropisms (63, 64). These studies assessed over 60
cell types: among them were lung-, colon-, central nervous system
(CNS)-, ovary-, renal-, and bladder-derived cell lines. Salivary
gland cells were not assessed.
BKPyV isolated from the TW of HIVSGD patients is likely
relevant to disease in the in vivo setting and has now undergone
initial in vitro characterization. High BKPyV VLs were detected in
the oral fluids of two individuals diagnosed with HIVSGD. We
identified a common NCCR block architecture among HIVSGD-
derived BKPyV isolates and successfully cultured clinical
HIVSGD-derived BKPyV in human salivary gland cells and in
kidney cells. Our assessment of a high-replication clinical isolate
and a low-replication clinical isolate suggested that a single point
mutation in Tag brought about the stark differences in the in vitro
replication potential. The high replicator (HIVSGD-1) surpassed
the replication potential of the kidney-derived isolate (U1) in hu-
man salivary gland cells, replicated efficiently in human salivary
gland and kidney cells, and displayed signs of salivary gland
tropism.
Our results are significant, as they corroborate a potential con-
nection between BKPyV and HIVSGD and provide an important
initial understanding of BKV replication in the oral compartment.
Our data suggest that HIVSGD TW-derived BKPyV displays pref-
erential tropism for salivary gland cells, and we have now proven
that wild-type oral-clinical BKV isolates undergo permissive rep-
lication in salivary gland cells in vitro. Permissive replication of
wild-type clinical BKV isolates previously thought to occur pre-
dominately in renal epithelium and uro-epithelium may be ongo-
ing at other sites as well. Saliva serves as a transmission vehicle for
many microorganisms, and our data corroborate previous data
showing that the oral compartment and saliva may function as a
transmission vehicle for BKPyV in vivo as well. The small number
of characterized HIVSGD isolates is a clear limitation of this cur-
rent study and thus may not be representative of all HIVSGD
variants. A study encompassing a larger number of isolates
would be more representative and needs to be performed. Impor-
tantly, this study provides a system for the study of clinical oral
BKPyV infection, and these observations provide insights for fu-
ture BKPyV pathogenesis, transmission, and disease association
studies.
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